此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

2026年9月16日 更新者:AbbVie

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ABBV-1758 in Participants With Alzheimer's Disease

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. The purpose of this study is to test how safe ABBV-1758 is, how well it works, how the body processes it and what effects it has on the body.

ABBV-1758 is an investigational drug being developed for the treatment of Alzheimer's disease. This study is conducted in 3 stages. Stage A is a multiple ascending dose study with a 1 in 5 chance (4:1 randomization) that participants are assigned to receive placebo. Stage B is a dose expansion phase, also using 4:1 randomization for ABBV-1758 or placebo. Stage C enrolls Japanese and Chinese participants with the same randomization scheme. Approximately 210 participants will be enrolled at about 55 sites in the United States, China, and Japan.

Participants will receive intravenous (IV) or subcutaneous (SC) doses of ABBV-1758 or placebo once every 4 weeks (Q4W) for 24 weeks and will be followed for additional 12 weeks in the Follow-up Period. Participants will have the option of participating in a 12-month, blinded Extension Period receiving ABBV-1758 or placebo based on amyloid PET results.

There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The safety of the treatment will be checked by medical assessments, blood tests, and completing questionnaires.

研究概览

研究类型

介入性

注册 (估计的)

210

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100053
        • 招聘中
        • Xuanwu Hospital Capital Medical University /ID# 283310
    • Guangdong
      • Guangzhou、Guangdong、中国、510260
        • 招聘中
        • The Second Affiliated Hospital of Guangzhou Medical University /ID# 284295
    • California
      • Irvine、California、美国、92614
        • 招聘中
        • Irvine Center for Clinical Research /ID# 277752
    • Colorado
      • Boulder、Colorado、美国、80301
        • 招聘中
        • Alpine Clinical Research Center - Boulder - 47th Street /ID# 277856
    • Florida
      • Bradenton、Florida、美国、34207
        • 招聘中
        • Key Clinical Research LLC /ID# 277800
        • 接触:
          • Site Coordinator
          • 电话号码:941-241-5539
      • Clermont、Florida、美国、34711
        • 招聘中
        • K2 Medical Research - Clermont /ID# 277859
      • Lady Lake、Florida、美国、32159
        • 招聘中
        • K2 Medical Research - The Villages /ID# 278290
      • Stuart、Florida、美国、34997
        • 招聘中
        • Alzheimer'S Research And Treatment Center - Stuart /ID# 278206
      • Wellington、Florida、美国、33414
        • 招聘中
        • Alzheimer's Research And Treatment Center - Wellington /ID# 277749
        • 接触:
          • Site Coordinator
          • 电话号码:(561) 209-2400
      • Winter Park、Florida、美国、32789
        • 招聘中
        • Conquest Research - Winter Park /ID# 277760
        • 接触:
          • Site Coordinator
          • 电话号码:407-916-0060
    • Massachusetts
      • Watertown、Massachusetts、美国、02472
        • 招聘中
        • Adams Clinical /ID# 277754
    • Tennessee
      • Cordova、Tennessee、美国、38018
        • 招聘中
        • Neurology Clinic - Cordova /ID# 277790
    • Texas
      • Dallas、Texas、美国、75231
        • 招聘中
        • Kerwin Medical Center /ID# 277788
        • 接触:
          • Site Coordinator
          • 电话号码:972-433-9100

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 至 90年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Participants meeting all the following criteria for Alzheimer's disease (AD):

    • In regions where timely testing is feasible (e.g., results available within 4 weeks of Visit 1), plasma biomarker that is predictive of elevated brain amyloid at Screening for participants that do not have known elevated brain amyloid based on previous amyloid positron emission tomography (PET) results.
    • Participants with amyloid positron emission tomography PET scan results consistent with significant amyloid pathology (as determined by a Centiloid value of 50 or higher).
  • Participants must have a Mini-Mental State Examination (MMSE) score of 20 or higher at Screening.

Exclusion Criteria:

  • Participants with screening magnetic resonance imaging (MRI) that show evidence of another potential etiology for progressive dementia.

  • Participants who have any current serious conditions or illnesses that are not adequately controlled, or any conditions that, in the investigator's opinion, could interfere with the analyses in this study, including but not limited to psychiatric, neurologic (other than AD), cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, immunologic, or hematologic, metabolic, pulmonary, ophthalmologic, dermatologic, and/or any history of abnormal laboratory results that are indicative of significant disease(s).

  • Participants who had prior exposure to ABBV-1758 or any history of exposure to anti-amyloid beta monoclonal antibody (mAb) treatment.

  • Participants with other significant pathological findings on brain MRI at screening, including but not limited to:

    • Evidence of vasogenic edema
    • 4 or more microhemorrhages (defined as 10 mm or less at the greatest diameter)
    • Any macrohemorrhage (defined as greater than 10 mm at the greatest diameter)
    • Any superficial siderosis
    • Severe white matter disease

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Stage A-ABBV-1758 Dose A

Participants will receive ABBV-1758 dose A once every 4 weeks (Q4W).

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

安慰剂比较:Placebo for ABBV-1758 Dose A

Participants will receive Placebo for ABBV-1758.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

实验性的:Stage A-ABBV-1758 Dose B

Participants will receive ABBV-1758 dose B Q4W.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

安慰剂比较:Placebo for ABBV-1758 Dose B

Participants will receive Placebo for ABBV-1758.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

实验性的:Stage A-ABBV-1758 Dose C

Participants will receive ABBV-1758 dose C Q4W.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

安慰剂比较:Placebo for ABBV-1758 Dose C

Participants will receive Placebo for ABBV-1758.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

实验性的:Stage A-ABBV-1758 Dose D

Participants will receive ABBV-1758 dose D Q4W.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

安慰剂比较:Placebo for ABBV-1758 Dose D

Participants will receive Placebo for ABBV-1758.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

实验性的:Stage B- ABBV-1758 - Expanded Cohort 1

Participants will receive ABBV-1758 dose determined in Stage A Q4W.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

安慰剂比较:Placebo for ABBV-1758 - Expanded Cohort 1

Participants will receive Placebo for ABBV-1758.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

实验性的:Stage B- ABBV-1758- Expanded Cohort 2

Participants will receive ABBV-1758 dose determined in Stage A Q4W.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

安慰剂比较:Placebo for ABBV-1758- Expanded Cohort 2

Participants will receive Placebo for ABBV-1758.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

实验性的:Stage C- ABBV-1758 - Japanese Cohort 1

Participants will receive ABBV-1758 dose determined in Stage A Q4W.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

安慰剂比较:Placebo for ABBV-1758 - Japanese Cohort 1

Participants will receive Placebo for ABBV-1758.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

实验性的:Stage C- ABBV-1758- Japanese Cohort 2

Participants will receive ABBV-1758 dose determined in Stage A Q4W.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

安慰剂比较:Placebo for ABBV-1758- Japanese Cohort 2

Participants will receive Placebo for ABBV-1758.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

实验性的:Stage C- ABBV-1758-Chinese Cohort

Participants will receive ABBV-1758 dose determined in Stage A Q4W.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

安慰剂比较:Placebo for ABBV-1758- Chinese Cohort

Participants will receive Placebo for ABBV-1758.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of Participants Experiencing Adverse Events (AEs)
大体时间:Up to approximately 40 weeks

An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.

Up to approximately 40 weeks
Percentage of Participants with Abnormal Change from Baseline in Clinical Laboratory Test Results
大体时间:Up to approximately 40 weeks

Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed.

Up to approximately 40 weeks
Percentage of Participants With Amyloid-Related Imaging Abnormalities (ARIA)
大体时间:Up to approximately 40 weeks

Amyloid related imaging abnormalities represent a spectrum of magnetic resonance imaging findings primarily observed in participants undergoing treatment with anti-amyloid therapies.

Up to approximately 40 weeks
Percentage of Participants with Abnormal Change From Baseline in Vital Sign Measurements
大体时间:Up to approximately 40 weeks

Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.

Up to approximately 40 weeks
Percentage of Participants with Abnormal Change From Baseline in Electrocardiograms (ECGs) Parameters
大体时间:Up to approximately 40 weeks

12-lead resting ECGs will be recorded. Parameters include heart rate, PR interval, QT interval, QRS duration, and QT interval corrected using Fridericia's formula (QTcF).

Up to approximately 40 weeks
Percentage of Participants Experiencing Any Suicidal Ideation or Suicidal Behavior As Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
大体时间:Up to approximately 40 weeks

The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior.

Up to approximately 40 weeks
Stage A, B, and C: Change from Baseline in Brain Amyloid Load
大体时间:Up to approximately 28 Weeks

Measured by amyloid positron emission tomography (PET)

Up to approximately 28 Weeks
Stage A and C: Maximum Plasma Concentration (Cmax) of ABBV-1758
大体时间:Up to approximately 40 weeks

Cmax of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Time to Cmax (Tmax) of ABBV-1758
大体时间:Up to approximately 40 weeks

Tmax of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Trough Concentration measured at the end of a dosing interval at steady state (Ctrough) of ABBV-1758
大体时间:Up to approximately 40 weeks

Ctrough of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Area under the Plasma Concentration-time Curve from Time Zero to the End of the Dosing Interval (AUCtau) of ABBV-1758
大体时间:Up to approximately 40 weeks

AUCtau of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Average Serum Concentration at Steady-State (Cav,ss) of ABBV-1758
大体时间:Up to approximately 40 weeks

Cav,ss of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Accumulation ratio for (AUCtau) of ABBV-1758
大体时间:Up to approximately 40 weeks

AUCtau of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Total Body Clearance (CL) of ABBV-1758
大体时间:Up to approximately 40 weeks

CL of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Apparent Clearance (CL/F) of ABBV-1758
大体时间:Up to approximately 40 weeks

CL/F of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Volume of Distribution at Steady-State (Vss)
大体时间:Up to approximately 40 weeks

Vss of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Apparent Volume of Distribution during the Terminal Phase (Vz)
大体时间:Up to approximately 40 weeks

Vz of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Terminal Phase Elimination Rate Constant (β) of ABBV-1758
大体时间:Up to approximately 40 weeks

β of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Terminal Phase Elimination Half-Life (t1/2) of ABBV-1758
大体时间:Up to approximately 40 weeks

Terminal phase elimination half-life of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Effective Half-Life (T1/2,eff)
大体时间:Up to approximately 40 weeks

T1/2,eff of ABBV-1758

Up to approximately 40 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:ABBVIE INC.、AbbVie

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月15日

初级完成 (估计的)

2030年10月1日

研究完成 (估计的)

2030年10月1日

研究注册日期

首次提交

2026年5月15日

首先提交符合 QC 标准的

2026年5月15日

首次发布 (实际的)

2026年5月20日

研究记录更新

最后更新发布 (实际的)

2026年9月18日

上次提交的符合 QC 标准的更新

2026年9月16日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

IPD 共享时间框架

For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

IPD 共享访问标准

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD 共享支持信息类型

  • 研究方案
  • 树液

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅